C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[C:19]([NH2:20])=[CH:18][N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.[Cl:21]C1C=C(Cl)N=C([N+]([O-])=O)N=1>>[ClH:21].[ClH:21].[N:11]1([C:14]2[C:19]([NH2:20])=[CH:18][N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]14-Piperazin-1-yl-pyrimidin-5-ylamine dihydrochloride was prepared by the procedures described in Example 34, Step 3, substituting (2R)-{1-(4-chlorobenzyl)-2-[4-(1H-indazol-5-yl)-piperazin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester with 4-(5-aminopyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (prepared from 4,6-dichloro-nitropyrimidine according to the procedures described in U.S. Pat. No. 5,563,142). LCMS (APCI+) m/z 180 [M+H]+; Rt=1.12 minutes.
Loading…